Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2020 · 10-Q
Revenue$85.81M$85.81M+8.6% vs Q2 2019 Net Income-$192.00K-$192.00KN/M vs Q2 2019 EPS Diluted$0.00$0.00−100.0% vs Q2 2019 Gross Profit$33,177,000+2.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$30,089,000−41.8% Free Cash Flowderived$19,200,000−54.3% Margins · derivedGross margin38.7%−2.3 pt vs Q2 2019
Operating margin-3.4%−4.6 pt vs Q2 2019
Net margin-0.2%−60.7 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 7, 2020 · 38 d after period end